Skip to main content
Skip to main content
ENMI logo

DH Enchantment Inc. (ENMI) Stock Analysis

$0.0001 +$0.00 (+0.00%) |CouncilBearish Lean · 34 · D
DH Enchantment Inc. (ENMI) bottom line: Bearish Lean — our Council read (34/100) and AI Score (42/100) broadly agree. Strongest signal: Izzy Englander bullish · Biggest watch-out: Seth Klarman bearish.
Vol: 18.2K| 52-wk range: $0.0001 – $0.0004
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

DH Enchantment Inc. (ENMI) trades at $0.0001 with AI Score 42/100 (Grade C). DH Enchantment Inc. distributes COVID-19 rapid antigen test kits in Hong Kong. Sector: Healthcare.

Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026
DH Enchantment Inc. distributes COVID-19 rapid antigen test kits in Hong Kong. The company primarily serves personal hygiene product distributors and operates through its subsidiary, Ho Shun Yi Limited.

Analyst Coverage for ENMI: ENMI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ENMI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.

Watch the ENMI film Every key number, told as a short cinematic story — just press play. ~2 min
Council Score · Weighted Average of 3 Disciplines
Bearish Lean 34/100 · D

ENMI: 2/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI
Ray Dalio
Bullish
Izzy Englander
Bullish
Seth Klarman
Neutral
Moon AI
Neutral
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Negative
Margin of Safety
Overvalued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →

Why this analysis is different

  • A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
  • An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
  • Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

DH Enchantment Inc. (ENMI) Healthcare & Pipeline Overview

CEOCheuk Yin Cheung
Employees1
HeadquartersKowloon, HK
IPO Year2010

DH Enchantment Inc. focuses on the distribution of COVID-19 rapid antigen test kits in Hong Kong, serving personal hygiene product distributors. Formerly Energy Management International, the company rebranded in 2021. With a negative profit margin and OTC listing, ENMI faces significant challenges in a competitive healthcare distribution market.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 17, 2026

What Is the Investment Thesis for ENMI?

As of Mar 17, 2026 — figures reflect the data available on that date.

Investing in DH Enchantment Inc. presents a high-risk, high-reward scenario. The company's focus on COVID-19 rapid antigen test kit distribution in Hong Kong offers potential upside, but its financial performance raises concerns. With a negative profit margin of -71.1% and a small market capitalization, the company's financial stability is questionable. The company's beta of 2.54 indicates high volatility. The success of ENMI hinges on its ability to secure and maintain distribution contracts, manage costs effectively, and adapt to evolving market demands for COVID-19 testing. Investors should closely monitor the company's financial performance and competitive positioning before considering an investment.

Based on FMP financials and quantitative analysis

ENMI Key Highlights

Market Cap of $0.00B indicates a micro-cap company with limited resources.

  • P/E Ratio of -0.72 reflects negative earnings, suggesting the company is currently unprofitable.
  • Profit Margin of -71.1% highlights significant challenges in achieving profitability.
  • Gross Margin of 32.1% indicates some efficiency in production and distribution, but is offset by high operating costs.
  • Beta of 2.54 suggests the stock is highly volatile compared to the overall market.

Who Are ENMI's Competitors?

ENMI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
KJFI Comjoyful International Company $0.97 +0.00% $212M 52
RDGT Ridgetech Inc. $0.81 -0.69% 45
PDRX PD-Rx Pharmaceuticals, Inc. $3.35 +0.00% $5.75M 44
WGRX Wellgistics Health, Inc. $3.52 +0.00% $8.67M
CQCQ MakingORG, Inc. $0.75 +0.00% $26.7M 61
HX Akso Health Group $2.24 -4.27% $53.4M 38
GEG Great Elm Group, Inc. $2.15 +0.00% $67.4M
ACH Accendra Health, Inc. (ACH) is a healthcare solutions company providing products and services to healthcare providers and patients. The company $1.31 -0.76% $100M

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ENMI's Key Strengths?

Established presence in the Hong Kong market.

  • Focus on COVID-19 rapid antigen test kit distribution.
  • Existing relationships with personal hygiene product distributors.

What Are ENMI's Weaknesses?

Negative profit margin.

  • Small market capitalization.
  • Limited product diversification.
  • Dependence on a single market (Hong Kong).

What Could Drive ENMI Stock Higher?

Potential new distribution agreements with healthcare providers.

  • Fluctuations in COVID-19 infection rates impacting demand for test kits.
  • Potential expansion into new geographic markets.

What Are the Key Risks for ENMI?

Financial-distress signal — its Altman Z-Score of -0.95 sits in the distress zone (elevated bankruptcy risk).

  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
  • Intense competition in the medical distribution industry.
  • Evolving regulatory requirements impacting product approvals.
  • Dependence on a single product category (COVID-19 rapid antigen test kits).
  • Supply chain disruptions affecting product availability.
  • Negative profit margin and financial instability.

What Are the Growth Opportunities for ENMI?

  • Expansion into New Markets: DH Enchantment Inc. could explore opportunities to expand its distribution network beyond Hong Kong. By targeting neighboring regions or countries with similar healthcare needs, the company could diversify its revenue streams and reduce its reliance on a single market. This expansion could involve establishing partnerships with local distributors or setting up its own distribution channels. The timeline for this expansion would depend on regulatory approvals and market entry strategies, potentially within the next 2-3 years.
  • Diversification of Product Portfolio: The company could diversify its product portfolio to include other medical diagnostic products or healthcare-related items. By offering a broader range of products, DH Enchantment Inc. could attract a wider customer base and increase its revenue potential. This diversification could involve partnering with other manufacturers or developing its own branded products. The timeline for this diversification could be within the next 1-2 years.
  • Strategic Partnerships: DH Enchantment Inc. could form strategic partnerships with healthcare providers, hospitals, or clinics to secure distribution contracts and increase its market reach. By collaborating with established healthcare institutions, the company could gain access to a larger customer base and enhance its reputation. These partnerships could involve exclusive distribution agreements or joint marketing initiatives. The timeline for establishing these partnerships could be within the next year.
  • Online Sales Platform: Developing an online sales platform could enable DH Enchantment Inc. to reach a wider customer base and streamline its distribution process. By offering its products directly to consumers through an e-commerce website, the company could reduce its reliance on traditional distribution channels and increase its profit margins. This online platform could also provide valuable data on customer preferences and market trends. The timeline for developing this online platform could be within the next 6-12 months.
  • Government Contracts: Securing government contracts to supply COVID-19 rapid antigen test kits could provide DH Enchantment Inc. with a stable revenue stream and enhance its credibility. By participating in government tenders and bidding processes, the company could gain access to large-scale procurement opportunities. These contracts could involve supplying test kits to schools, hospitals, or other public institutions. The timeline for securing these contracts would depend on the government's procurement schedules and the company's ability to meet the required specifications.

What Are ENMI's Competitive Advantages?

  • Established distribution network in Hong Kong.
  • Existing relationships with personal hygiene product distributors.
  • Focus on a specific niche market (COVID-19 rapid antigen test kits).

What Does ENMI Do?

DH Enchantment Inc., established in 2004 and based in Kowloon, Hong Kong, operates in the healthcare sector as a distributor of COVID-19 rapid antigen test kits. Through its subsidiary, Ho Shun Yi Limited, the company focuses on supplying these test kits to personal hygiene product distributors within Hong Kong. Originally incorporated as Energy Management International, Inc., the company underwent a name change in August 2021 to DH Enchantment Inc., signaling a shift in its business focus. The company's current operations are centered around the distribution of medical diagnostic products, specifically catering to the increased demand for COVID-19 testing solutions. With a small team of one employee, DH Enchantment Inc. navigates a competitive market landscape, striving to maintain its position as a key supplier of essential healthcare products in the region. The company's ability to adapt to changing market dynamics and regulatory requirements will be critical to its long-term success.

What Products and Services Does ENMI Offer?

  • Distributes COVID-19 rapid antigen test kits.
  • Operates through its subsidiary, Ho Shun Yi Limited.
  • Serves personal hygiene product distributors in Hong Kong.
  • Focuses on supplying medical diagnostic products.
  • Caters to the demand for COVID-19 testing solutions.

How Does ENMI Make Money?

  • Procures COVID-19 rapid antigen test kits from manufacturers.
  • Distributes these test kits to personal hygiene product distributors.
  • Generates revenue through the sale of test kits.
  • Focuses on serving the Hong Kong market.

What Industry Does ENMI Operate In?

DH Enchantment Inc. operates within the medical distribution industry, specifically focusing on COVID-19 rapid antigen test kits. The industry is characterized by intense competition, evolving regulatory requirements, and fluctuating demand based on public health conditions. The company's success depends on its ability to secure distribution contracts, manage supply chains effectively, and adapt to changing market dynamics. Competitors include companies like CBDG, CSTF, DPAT, KJFI, and LVTTF, all vying for market share in the healthcare distribution sector. The demand for COVID-19 testing products is subject to changes in infection rates and government policies, creating both opportunities and challenges for DH Enchantment Inc.

Who Are ENMI's Key Customers?

  • Personal hygiene product distributors in Hong Kong.
  • Healthcare providers.
  • Hospitals and clinics.
AI Confidence: 67% Updated: Mar 17, 2026

How DH Enchantment Inc. Is Valued

Relative to its peer group, ENMI's quantitative score of 42/100 is roughly in line with the peer average of 51/100.

Company Profile

DH Enchantment Inc. operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Hong Kong, HK. The company is led by CEO Cheuk Yin Cheung. ENMI has traded publicly since 2010.

ROE 17%

Key Financial Metrics

Return on equity for DH Enchantment Inc. stands at 17.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -30.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -187.8%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9

Financial Health

DH Enchantment Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.95 places it in the distress zone, a signal of elevated financial risk.

ENMI Financials

Fundamental Snapshot

Revenue Growth (FY)
-95.5%
Net Income Growth (FY)
+59.5%
EPS Growth (FY)
+60.0%
Free Cash Flow Growth (FY)
-0.1%
Return on Equity (TTM)
+17.3%

Based on FMP financials and quantitative analysis · FY 2024

Bull Case vs Bear Case

Bull Case

  • Established presence in the Hong Kong market.
  • Focus on COVID-19 rapid antigen test kit distribution.
  • Existing relationships with personal hygiene product distributors.
  • Upcoming: Potential new distribution agreements with healthcare providers.

Bear Case

  • Negative profit margin.
  • Small market capitalization.
  • Limited product diversification.
  • Dependence on a single market (Hong Kong).

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026

ENMI Latest News

No recent news available for ENMI.

ENMI Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ENMI.

Price Targets

Wall Street price target analysis for ENMI.

ENMI MoonshotScore

42/100

What does this score mean?

The MoonshotScore rates ENMI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.

Leadership: Cheuk Yin Cheung

Unknown

Information on Cheuk Yin Cheung's background is not available. Details regarding their career history, education, and previous roles are unknown. Further research is needed to gather more information about their professional experience and qualifications.

Track Record: Information on Cheuk Yin Cheung's track record is not available. Specific achievements, strategic decisions, and company milestones under their leadership are unknown. Further research is needed to assess their performance and impact on the company.

ENMI OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for trading on OTCQX or OTCQB. Companies in this tier often face challenges related to financial reporting, regulatory compliance, and corporate governance. These securities may lack readily available information and are subject to higher levels of risk and volatility compared to those listed on higher tiers or major exchanges like NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before considering investments in OTC Other securities.

  • OTC Tier: OTC Other
Liquidity: Liquidity for ENMI is likely very limited given its OTC Other listing and small market capitalization. Expect wide bid-ask spreads and difficulty in executing large trades without significantly impacting the price. This lack of liquidity increases the risk of holding the stock, as it may be challenging to exit the position quickly or at a desired price.
OTC Risk Factors:
  • Limited financial disclosure due to OTC Other listing.
  • High volatility and price fluctuations.
  • Potential for fraud or manipulation.
  • Lack of regulatory oversight.
  • Limited liquidity and difficulty in trading shares.
Due Diligence Checklist:
  • Verify the company's registration and legal status.
  • Review available financial statements and disclosures.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team and their track record.
  • Understand the risks associated with investing in OTC securities.
  • Consult with a financial advisor.
  • Monitor news and developments related to the company.
Legitimacy Signals:
  • Company has been in operation since 2004.
  • Company has a subsidiary, Ho Shun Yi Limited.
  • Company distributes COVID-19 rapid antigen test kits.

DH Enchantment Inc. Healthcare Stock: Key Questions Answered

What does the AI Score mean for ENMI?

ENMI holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. DH Enchantment Inc. distributes COVID-19 rapid antigen test kits in Hong Kong. The company primarily serves personal hygiene product distributors and operates through its subsidiary, Ho Shun Yi …

What does DH Enchantment Inc. do?

DH Enchantment Inc. operates as a distributor of COVID-19 rapid antigen test kits in Hong Kong, primarily serving personal hygiene product distributors. Through its subsidiary, Ho Shun Yi Limited, the company focuses on supplying these test kits to meet the demand for rapid testing solutions.

What do analysts say about ENMI stock?

As of 2026-03-17, there is no available analyst coverage for DH Enchantment Inc. due to its OTC listing and small market capitalization. Key valuation metrics such as price targets and ratings are not available. Investors should conduct their own independent research and due diligence before considering an investment in ENMI.

What are the main risks for ENMI?

Investing in DH Enchantment Inc. involves several risks, including its negative profit margin, small market capitalization, and dependence on a single product category (COVID-19 rapid antigen test kits). The company operates in a competitive industry with evolving regulatory requirements and fluctuating demand. Supply chain disruptions could also impact product availability.

What are the key factors to evaluate for ENMI?

DH Enchantment Inc. (ENMI) holds an AI score of 42/100 (low). Investing in DH Enchantment Inc. presents a high-risk, high-reward scenario. Not financial advice.

How frequently does ENMI data refresh on this page?

ENMI's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.

What has driven ENMI's recent stock price performance?

DH Enchantment Inc. (ENMI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the Hong Kong market. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ENMI overvalued or undervalued right now?

DH Enchantment Inc. (ENMI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research ENMI before investing?

Before investing in DH Enchantment Inc. (ENMI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited information available on the company's financials and operations.
  • OTC listing increases the risk of investing in this stock.
  • Lack of analyst coverage.
Data Sources

Popular Stocks

More Stocks We Cover